AGA Family of Websites: Gastro.org
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
June 4, 2019

What factors determine if a pediatric IBD patient is at high risk for complications?

Athos Bousvaros, MD, AGAF, and Andrew Grossman, MD, discuss the biggest takeaways from the Pediatric IBD: The State of the Art workshop.

Share on facebook
Share on twitter
Share on linkedin
Share on email

On Feb. 7-9, 2019, inflammatory bowel disease (IBD) professionals gathered at the second annual Crohn’s & Colitis Congress® to discuss how to transform IBD care. 

In a video filmed during the Crohn’s & Colitis Congress, Athos Bousvaros, MD, AGAF, and Andrew Grossman, MD, discussed the biggest takeaways from the Pediatric IBD: The State of the Art workshop. These include:

  • Importance of serological markers to risk-stratify patients and if needed to recommend more aggressive therapies, like biologics.
  • Optimizing the use of proactive therapeutic drug monitoring to achieve mucosal healing and disease remission.

Don’t miss the latest updates in treating pediatric IBD. Save the date for the 2020 Crohn’s & Colitis Congress, taking place Jan. 23-25, 2020, in Austin, Texas. Visit www.crohnscolitiscongress.org to register as of June 27, 2019.

Additional video highlights from the 2019 Crohn’s & Colitis Congress can be viewed here

Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.